Clene Inc. (CLNN)

Current Report Filed: 2026-05-14

Key Insights

Clene secured a critical debt restructuring with a second amendment to convertible notes, extending the maturity date to August 13, 2027 and deferring $1 million monthly payments that were set to begin September 2026, providing near-term liquidity relief.
The company faces significant related-party concentration risk, with all three note holders having material connections to Clene's operations: Kensington controlled by board member Alison Mosca, 4Life holding supply agreements with Clene's subsidiary, and La Scala controlled by 4Life's co-founder who sits on the subsidiary's board.
The deferral of debt payments indicates potential liquidity constraints, as the full principal and accrued interest balance is now due by August 2027, creating a material refinancing or repayment obligation within approximately 15 months.
Q1 2026 financial results were announced alongside this debt restructuring, suggesting the company may be facing operational or financial headwinds that necessitated the amended payment terms.

Quarterly Report Filed: 2026-05-14

Key Insights

Clene completed a January 2026 public equity offering issuing Series A and Series B Warrants with aggressive call provisions, suggesting the company raised capital but faces potential warrant dilution if stock price appreciates significantly.
Multiple warrant tranches remain unexercised as of March 31, 2026 (Series A, Series B, Tranche A, Tranche B, and 2024 Common Warrants), indicating the stock price has not reached exercise thresholds, which may reflect weak market performance or investor confidence concerns.
The company is dependent on FDA approval milestones for CNM-Au8, with Tranche A and B Warrants expiring upon FDA announcement/approval in June 2026 or June 2030 respectively, creating significant near-term regulatory catalysts and execution risk.
The filing shows substantial accrued liabilities including deferred employee compensation ($1.1 million in stock options), suggesting cash constraints and reliance on equity-based compensation to preserve liquidity.

Insider Trading Filed: 2026-05-05

Key Insights

Director Ugwumba Chidozie sold 78,679 shares across two transactions (5,795 shares on 05/01/2026 at $6.01 and 72,884 shares on 05/04/2026 at $6.80), reducing indirect beneficial ownership from 271,774 to 198,890 shares held through SymBiosis II, LLC.
Both sales occurred at relatively modest price points ($6.01-$6.80), suggesting the director executed sales during a period of limited stock appreciation, which could indicate lack of confidence in near-term price catalysts.
The sales represent a meaningful 29% reduction in the director's beneficial ownership stake within a 4-day period, though sales remain entirely indirect through a related entity rather than direct personal holdings.
All transactions were properly disclosed through indirect ownership structures, with no derivative securities activities reported, indicating routine portfolio management by an insider with director-level responsibilities.

Current Report Filed: 2026-05-05

Key Insights

Clene Inc. is raising $7 million gross proceeds ($6.4 million net) through a public offering of 1 million shares at $7.00 per share, indicating potential cash needs for clinical development and commercialization activities.
The company plans to deploy capital toward NDA preparation and filing for its lead drug candidate CNM-Au8, expanded access protocols, Phase 3 clinical trials, and manufacturing expansion, suggesting progress in advancing its pipeline toward commercialization.
A 60-day lock-up agreement restricts company insiders and directors from selling shares post-offering, which is standard practice but limits insider liquidity and demonstrates underwriter confidence in the offering.
The offering is priced at $7.00 per share through an S-3 registration statement, with Canaccord Genuity as sole bookrunner and the company also maintaining an equity distribution agreement with the same underwriter for future capital raises.

Current Report Filed: 2026-05-04

Key Insights

FDA confirmed that CNM-Au8's neurofilament light (NfL) biomarker data may support an accelerated approval NDA pathway for ALS treatment, with the agency indicating NfL could serve as a reasonably likely surrogate endpoint—a significant regulatory validation that de-risks the approval process.
Company plans to submit the NDA in Q3 2026 and initiate a Phase 3 confirmatory trial in Q1 2027, demonstrating a clear timeline for regulatory advancement that could position the company for potential accelerated approval while conducting the standard confirmatory study.
The NDA submission will be supported by multiple data sources including Phase 2 HEALEY ALS Platform Trial, open-label extension showing reduced NfL associated with longer survival, Phase 2 RESCUE-ALS Trial, and an NIH-sponsored Expanded Access Protocol, providing robust clinical and biomarker evidence.
CNM-Au8 has already received Orphan Drug Designation for ALS, which provides regulatory benefits including potential market exclusivity and expedited review, strengthening the commercial viability if approved.

Insider Trading Filed: 2026-04-30

Key Insights

Director Ugwumba Chidozie executed three consecutive sales of common stock over a 2-day period (04/28-04/30/2026), totaling 19,497 shares, reducing beneficial ownership from approximately 295,475 to 277,569 shares.
All sales were conducted at relatively low price points ($5.63-$6.08 range), suggesting the insider may be taking profits or rebalancing holdings during a period of modest stock valuation.
The shares were sold indirectly through SymBiosis II, LLC, indicating a structured ownership arrangement typical of insider holdings, with no derivative securities activity reported.

Insider Trading Filed: 2026-04-22

Key Insights

Director Ugwumba Chidozie executed two substantial sales totaling 65,663 shares of CLNN common stock over two consecutive trading days (04/20-04/21/2026) at prices ranging from $6.12-$6.14, reducing his indirect beneficial ownership by approximately 18%.
All shares were sold indirectly through SymBiosis II, LLC, indicating a structured divestment rather than opportunistic selling, which may suggest strategic portfolio rebalancing or liquidity needs by this significant insider.
The timing of consecutive day sales at relatively stable pricing ($6.12-$6.14) during a coordinated two-day window raises questions about the motivation behind the substantial insider liquidation by a director-level stakeholder.

Insider Trading Filed: 2026-04-06

Key Insights

Chidozie Ugwumba, a director of Clene Inc. (CLNN), sold 24,925 shares of the company's common stock on April 2, 2026 at a price of $4.81 per share.
Following the reported transaction, Ugwumba now beneficially owns 401,891 shares of Clene Inc. indirectly through SymBiosis II, LLC.
The sale of shares by a director could signal a potential change in sentiment or outlook for the company, which investors should monitor closely.

Insider Trading Filed: 2026-04-01

Key Insights

Chidozie Ugwumba, a 10% owner of Clene Inc. (CLNN), sold 4,278 shares of common stock on April 1, 2026 at an average price of $4.97 per share.
This transaction reduced Ugwumba's beneficial ownership of Clene Inc. common stock to 426,816 shares, which he holds indirectly through SymBiosis II, LLC.
Insider selling can sometimes signal a lack of confidence in the company's future prospects, so this transaction may be viewed as a potentially negative signal by investors.

Insider Trading Filed: 2026-03-31

Key Insights

Chidozie Ugwumba, a director of Clene Inc. (CLNN), has sold a significant portion of his indirect holdings in the company, reducing his stake from 514,621 shares to 431,094 shares over the past three trading days.
The sales were made at prices ranging from $4.75 to $5.10 per share, suggesting Ugwumba may have been taking profits or rebalancing his portfolio.
Investors should monitor insider trading activity and assess whether Ugwumba's sales are a signal of his confidence in the company's future prospects.

Insider Trading Filed: 2026-03-26

Key Insights

Chidozie Ugwumba, a director of Clene Inc. (CLNN), has been selling a significant amount of the company's common stock over the past three trading days, disposing of over 17,900 shares in total.
The sales were executed at prices ranging from $5.40 to $5.78 per share, suggesting Ugwumba may have concerns about the company's current valuation or near-term prospects.
Investors should monitor whether this insider selling activity continues, as it could signal a potential lack of confidence in the company's outlook from a key director.

Annual Report Filed: 2026-03-17

Key Insights

Clene Inc. experienced a significant increase in cash and cash equivalents, reaching $600 million as of December 31, 2025, which could provide ample liquidity to fund ongoing operations and development of their pipeline.
The company has made substantial investments in property, plant, and equipment, potentially indicating expansion and capacity building to support future growth.
Clene Inc. has secured various grant funding and subward agreements, which could provide non-dilutive financing to support their research and development efforts.

Current Report Filed: 2026-03-17

Key Insights

Clene Inc. has secured a $8 million subaward agreement with New York University for the third year of a $45.1 million grant from the National Institutes of Health to support an Expanded Access Program for their CNM-Au8 treatment of amyotrophic lateral sclerosis.
The agreement allows Clene to use its pre-existing background intellectual property without granting any licenses to NYU or the U.S. government, preserving its proprietary technology.
The continued funding from the NIH grant demonstrates the government's support for Clene's efforts to accelerate access to critical therapies for ALS patients.

Current Report Filed: 2026-03-12

Key Insights

Clene Inc. reported its full year 2025 financial results, providing investors with an update on the company's recent operational performance.
The company did not provide any forward-looking guidance or commentary on upcoming milestones, limiting insights into its future plans and growth prospects.
Without additional details on key metrics, drivers, or strategic initiatives, the filing lacks substantive information for investors to fully assess Clene's current position and outlook.

Current Report Filed: 2026-02-24